First-in-Human Clinical Trial of the Galaxy System
Robotic Electromagnetic Navigation Bronchoscopy with
Integrated Tool-in-lesion-Tomosynthesis Technology
THE FRONTIER STUDY
AABIP 2023 Abstract Presentation; Tajalli Saghaie, Jonathan Williamson, Martin Philips, Dona Kafili, Sarika Sundar, Alvin Ing, Kyle Hogarth
The Galaxy System™ is currently the only robotic bronchoscopy system that has integrated Tool-in-Lesion-Tomography (TiLT) technology which enables real-time lesion updates supporting correction of CT-to-body divergence.
Having conducted pre-clinical studies that demonstrated satisfactory performance in safely achieving successful peripheral lung nodule biopsy,1 further validation of performance (safety and efficacy) in human clinical trials was needed. It is hypothesized that integrating TiLT+ Technology™ may further improve accuracy and yield.
Study Objective: The primary objective of this study was to evaluate the safety and feasibility of using the Galaxy System to bronchoscopically biopsy small peripheral pulmonary nodules between 1-3 cm.
Robotic bronchoscopy was performed under general anesthesia using electromagnetic navigation guidance with TiLT-assisted lesion sampling using a combination of transbronchial needles, forceps and cryoprobes.
Patients were followed up for up to 6 months.
|Number of Patients
|Number of Nodules
|Average Lesion Size
|Average Distance to Pleura
Estimated Diagnostic Yield*
*Pending patient follow up
1 “Tool-in-lesion” Accuracy of Galaxy System – A Robotic Electromagnetic Navigation Bronchoscopy With Integrated Tool-in-lesion-Tomosynthesis Technology: The MATCH Study Krish Bhadra, MD, Otis B. Rickman, DO, Amit K. Mahajan, MD, and Douglas Kyle Hogarth, MD